Introduction
============

Ovarian cancer is the leading cause of death among gynecological malignancies, and is also the fourth most common malignancy in women in developed countries, following breast, lung, and colorectal cancer ([@b1-ol-0-0-7726],[@b2-ol-0-0-7726]). Apart from surgery and radiotherapy, a substantial number of ovarian cancer patients commonly undergo chemotherapy because of its high efficacy. However, some of these patients frequently develop varying degrees of chemotherapeutic resistance, which is closely associated with the histological subtypes. Each of the ovarian cancers, represented by serous carcinoma (SEC), endometrioid carcinoma (EMC), clear cell carcinoma (CCC) and mucinous carcinoma (MUC), is known to have a specific prognosis and chemotherapy sensitivity.

Histone deacetylases (HDACs) are chromatin-modifying enzymes that are involved in regulation of many aspects of cell biology, including tissue differentiation, autophagy, apoptosis, migration, mitosis and angiogenesis via deacetylation of histone or non-histone protein ([@b3-ol-0-0-7726]). The HDAC family contains 18 enzymes and is divided into four classes based on their sequences similar to the yeast. In terms of enzymatic activity, HDAC1, 2, 3 and 8 for class I, HDAC4, 5, 6, 7, 9 and 10 for class II, and HDAC11 for class IV are zinc-dependent, and SIRT1-SIRT7 for class III are NAD+ dependent. Class I HDACs are considered as nuclear proteins and class II HDACs shuttle between the nucleus and cytoplasm ([@b4-ol-0-0-7726]). In several cancers including ovarian cancer, class I HDACs are upregulated and high HDAC1 expression is associated with a poor prognosis ([@b5-ol-0-0-7726]--[@b10-ol-0-0-7726]). *In vitro*, pan-HDAC inhibitor has been demonstrated to have a cytotoxic effect for ovarian cancer cell lines ([@b11-ol-0-0-7726]). However, the clinical trials resulted in limited therapeutic effect of pan-HDAC inhibitor because of the side toxicity ([@b12-ol-0-0-7726]). Therefore, more selective and effective HDACs inhibitors are needed in the therapy for ovarian cancers.

This study was conducted to analyze the association between immunohistochemical HDACs expression and clinicopathological findings, especially focusing on histological subtypes, prognosis and chemotherapy, with the aim at exploration of the new possible therapeutic strategies for ovarian cancer.

Materials and methods
=====================

### Patient data and clinicopathological features ([Table I](#tI-ol-0-0-7726){ref-type="table"})

Patient electronic medical charts from the Saitama Medical University International Medical Center from 2008 to 2012 were reviewed under approval of the Institutional Review Board (IRB) following the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1975, as revised in 1983. A total of 201 epithelial ovarian cancer patients (SEC, 100 cases; CCC, 56 cases; EMC, 36 cases; MUC, 9 cases) without preoperative chemotherapy, whose tumors were surgically resected and pathologically confirmed, were recruited in this study. We also obtained the specimens of 38 tumors (34 for SEC; 1 for CCC; 3 for EMC) after chemotherapy in addition to before chemotherapy in the same case. Clinicopathological characteristics with these cases, such as age, menopause, parity, recurrence, death, progression free survival (PFS), overall survival (OS), and the International Federation of Obstetrics and Gynecology (FIGO) stage, and treatment methods were reviewed.

### Immunohistochemistry staining

Immunohistochemical expression of HDACs was analyzed using tissue microarray (TMA: KIN-2; Azumaya, Tokyo, Japan) under approval of the IRB. TMA was generated from 2 cylindrical cores 3.0 mm in diameter in each block, which were punched out of paraffin-embedded tissue blocks corresponding to the representative histological findings and were inserted into a recipient block. The tissue blocks consisted of 201 cases with primary tumors which did not undergo neo-adjuvant chemotherapy. In addition, 38 tissue blocks in which the tumors had undergone chemotherapy were used. The total of 239 tissue blocks were cut into 4-µm serial sections, which were run through an automated system by Dako Autostainer Link 48 (Agilent Technologies, Inc., Santa Clara, CA, USA) as per manufacturer\'s protocol. The primary antibodies used were as follows: Polyclonal rabbit anti-HDAC1 (dilution:15,000; ab19845; Abcam, Cambridge, UK); monoclonal rabbit anti-HDAC2 (dilution, 1:1,000; ab32117; Abcam); monoclonal rabbit anti-HDAC3 (dilution, 1:250; ab32369; Abcam); polyclonal rabbit anti-HDAC4 (dilution, 1:500; ab12172; Abcam); polyclonal rabbit anti-HDAC5 (dilution, 1:200; ab55403; Abcam); polyclonal rabbit anti-HDAC6 (dilution, 1:500; ab1440; Abcam); and polyclonal rabbit anti-HDAC7 (dilution, 1:100; NB100-61587; Novus Biological, Colorado, USA). For all antibodies but HDAC7, Target Retrieval Solution (pH 9.0) was applied for the antigen retrieval at 98°C for 20 min. Sections were incubated with the primary antibodies at room temperature (RT) for 60 min, followed by incubation with a secondary antibody (EnVision FLEX/HRP; Agilent Technologies, Inc.) at RT for 30 min. The chromogen reaction was performed with diaminobenzidine plus the H~2~O~2~ substrate at RT for 10 min. It was confirmed that there are no significant differences in all of HDACs expressions between TMA and the whole section, using 20 randomized cases (data not shown).

### Interpretation of immunohistochemical results

Diagnoses were performed by one experienced pathologist who was blind to clinical data and patient characteristics, and one physician with a subspecialty in gynecological oncology. A four-tiered scoring scheme was used for both nuclear expression ([Fig. 1A](#f1-ol-0-0-7726){ref-type="fig"}) and cytoplasmic expression ([Fig. 1B](#f1-ol-0-0-7726){ref-type="fig"}), respectively: 0 for negative; +1 for weak; +2 for moderate; and +3 for marked. To optimize for PFS and OS differences, the raw data were binarized for statistical analysis as follows: The moderate (+2) and marked (+3) cases were grouped as high-level expressers, whereas the completely negative (0) and weak (+1) cases were considered as low-level expressers.

### Statistical analysis

Univariable survival analysis was performed by the generation of Kaplan-Meier curves, and differences between the groups were assessed using the log rank statistic. Univariable and multivariable survival analysis was performed using the Cox proportional hazards model. Kruskal-Wallis tests were used to assess the change in the distribution of HDAC expression across primary histological subtypes. Wilcoxon signed-rank test was used to assess the change between before and after chemotherapy. All analyses were performed using SPSS v24.0 (SPSS, Inc, Chicago, IL, USA). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Correlation of HDACs expression with histological subtype

HDACs overexpressions of each histological subtype are shown in [Fig. 2A](#f2-ol-0-0-7726){ref-type="fig"}. Expressions of HDAC1, 2, and 3 were observed only in the nucleus. Overexpression of HDAC1 was detected in all cases with MUC, followed by CCC (80%), SEC (73%), and EMC (53%). HDAC2 expression was observed in EMC (75%) and SEC (68%). HDAC3 expression was done in MUC (67%) and CCC (46%). CCC showed the highest frequency of HDAC7 (27%) and HDAC6 (34%) expression in the nucleus among all the subtypes. On the other hand, CCC showed the lowest frequency of HDAC5 cytoplasmic expression (30%). There were no significant differences in HDAC4 expression in both nucleus and cytoplasm and HDAC6 cytoplasmic expression among the histological subtypes. We analyzed the HDACs expressions of each FIGO stage in SEC ([Fig. 2B](#f2-ol-0-0-7726){ref-type="fig"}), CCC ([Fig. 2C](#f2-ol-0-0-7726){ref-type="fig"}), and EMC ([Fig. 2D](#f2-ol-0-0-7726){ref-type="fig"}). In SEC, FIGO stage I/II (83/67%) showed higher frequency of HDAC4 nuclear expression than stage III/IV (24/28%). In CCC, FIGO stage I (66%) showed higher frequency of HDAC2 nuclear expression than stage II (14%). There were no significant differences in other HDACs expression among each FIGO stage.

### Correlation of HDACs expression with chemotherapy ([Table II](#tII-ol-0-0-7726){ref-type="table"})

The chemotherapy responses were evaluated as follows: 38 ovarian cancers clinically are 3 for complete response (CR), 31 for partial response (PR), 2 for stable disease (SD), and 2 for progressive disease (PD). In the comparison between before and after chemotherapy, HDAC1 nuclear expression increased from 76 to 92% (P=0.03); HDAC7 expression in nucleus from 0 to 16% (P=0.01) in cytoplasm from 16 to 66% (P=\<0.01); HDAC6 cytoplasmic expression increased from 39 to 74% (P=\<0.01). No significant changes were noted in other types of HDAC. We analyzed the CR+PR group (n=35) and SD+PD group (n=3), and found that in the CR+PR group, HDAC1, 6, and 7 nuclear expressions and HDAC7 cytoplasmic expression increased in the comparison between before and after chemotherapy. In PD+PR group, no significant changes were noted in all types of HDAC.

### Correlation of HDACs expression with prognosis

In SEC, overexpression of HDAC1 in the nucleus was significantly associated with the decrease in PFS (P=\<0.01, [Fig. 3A](#f3-ol-0-0-7726){ref-type="fig"}) and OS (P=0.02, [Fig. 3B](#f3-ol-0-0-7726){ref-type="fig"}), but overexpression of HDAC7 in the cytoplasm had no significant adverse effect for PFS (P=0.35, [Fig. 3C](#f3-ol-0-0-7726){ref-type="fig"}) and OS (P=0.76, [Fig. 3D](#f3-ol-0-0-7726){ref-type="fig"}). Also in EMC, overexpression of HDAC1 in the nucleus was significantly associated with the decrease in PFS (P=0.03, [Fig. 3E](#f3-ol-0-0-7726){ref-type="fig"}) and OS (P=0.03, [Fig. 3F](#f3-ol-0-0-7726){ref-type="fig"}), but overexpression of HDAC7 in the cytoplasm had no significant adverse effect for PFS (P=0.42, [Fig. 3G](#f3-ol-0-0-7726){ref-type="fig"}) and OS (P=0.18, [Fig. 3H](#f3-ol-0-0-7726){ref-type="fig"}). In CCC, however, nuclear expression of HDAC1 showed no significant adverse effect for PFS (P=0.17, [Fig. 3I](#f3-ol-0-0-7726){ref-type="fig"}) and OS (P=0.68, [Fig. 3J](#f3-ol-0-0-7726){ref-type="fig"}); on the other hand, cytoplasmic expression of HDAC7 was correlated with poor prognostic factor (PFS, P=0.03; OS, P=0.06, [Fig. 3K, L](#f3-ol-0-0-7726){ref-type="fig"}). In the analysis focusing on the subgroup of FIGO stage I/II and stage III/IV in SEC and CCC ([Fig. 3M-T](#f3-ol-0-0-7726){ref-type="fig"}), SEC patients with HDAC1 nuclear overexpression tended to have a poor prognosis in FIGO stage III/IV (PFS, P=0.06; OS, P=0.15), but had no significant effect on a prognosis in stage I/II (PFS, P=0.40; OS, P=0.21). CCC patients with HDAC7 cytoplasmic overexpression showed a poor prognosis in FIGO stage I/II (PFS, P=0.02; OS, P=0.047), but had no significant effect on a prognosis in stage III/IV (PFS, P=0.76; OS, P=0.76). HDAC5 cytoplasmic expression in EMC was associated with poor prognosis (PFS, P=0.01; OS, P=0.05). HDAC4 nuclear expression in SEC was associated with longer PFS (P=0.03), but no significant change of OS (P=0.13). HDAC2, 3, and 6 in each of the histological types had no significant effect on the prognosis.

### Univariate and multivariate analyses ([Table III](#tIII-ol-0-0-7726){ref-type="table"})

In univariate analysis, OS was associated with histological subtype, FIGO stage, surgical residual tumor, HDAC1 nuclear expression (hazard ratio (HR)=2.06; 95% confidence interval (CI)=1.10 to 3.87; P=0.02) and HDAC5 cytoplasmic expression (HR=2.54; 95% CI, 1.46 to 4.42; P=\<0.01). In multivariate survival analysis performed under inclusion of age, histological subtype, FIGO stage, surgical residual tumor, and HDACs expression, FIGO stage (HR=10.8; 95% CI, 3.67 to 32.0; P=\<0.01), surgical residual tumor (HR=11.1; 95% CI, 3.32 to 37.4; P=\<0.01), histological subtype, and HDAC6 nuclear expression (HR=3.51; 95% CI, 1.49 to 8.27, P=\<0.01) were found to become the independent prognostic factors. In the analysis with the subgroup of HDAC6 nuclear expression ([Fig. 4](#f4-ol-0-0-7726){ref-type="fig"}), overexpression of HDAC6 in the nucleus had no significant adverse effect for OS in all cases (P=0.85, [Fig. 4A](#f4-ol-0-0-7726){ref-type="fig"}), SEC (P=0.69, [Fig. 4B](#f4-ol-0-0-7726){ref-type="fig"}), EMC (P=0.35, [Fig. 4D](#f4-ol-0-0-7726){ref-type="fig"}), FIGO stage I/II (P=0.44, [Fig. 4E](#f4-ol-0-0-7726){ref-type="fig"}), and optimal surgery (P=0.34, [Fig. 4G](#f4-ol-0-0-7726){ref-type="fig"}), but was associated with the decrease OS in CCC (P=0.07, [Fig. 4C](#f4-ol-0-0-7726){ref-type="fig"}), FIGO stage III/IV (P=0.07, [Fig. 4F](#f4-ol-0-0-7726){ref-type="fig"}), and suboptimal surgery (P=\<0.01, [Fig. 4H](#f4-ol-0-0-7726){ref-type="fig"}).

Discussion
==========

It has been reported that class I HDACs are upregulated and high HDAC1 expression is associated with poor prognosis in several cancers including ovarian cancer ([@b5-ol-0-0-7726]--[@b10-ol-0-0-7726]). Class I HDACs are involved in regulation of many aspects of cancer biology including cell proliferation via p21, p27, and p57 ([@b13-ol-0-0-7726],[@b14-ol-0-0-7726]), apoptosis via p53, bcl2, caspase-3, −8, and −9 ([@b15-ol-0-0-7726]), metastasis via e-cadherin ([@b10-ol-0-0-7726]), angiogenesis via hypoxia inducible factors-1α (HIF-1α) and vascular endothelial growth factor (VEGF) ([@b16-ol-0-0-7726],[@b17-ol-0-0-7726]), and anti-tumor immune responses via programmed death-1 ligand (PD-L1) ([@b18-ol-0-0-7726]). Weichert *et al* reported that overexpression of HDAC1 was an independent prognostic factor in ovarian EMC ([@b9-ol-0-0-7726]); however, the multivariable analysis does not contain the key prognostic factor in ovarian cancer, such as surgical debulking status (optimal or suboptimal). Hayashi *et al* ([@b10-ol-0-0-7726]) reported that overexpression of HDAC1 might be correlated with a poor prognosis in ovarian cancer, but did not analyze each of the histological subtypes in detail. Additionally, those two previous studies had not conducted an evaluation about class II HDACs. The present study was designed to supplement the deficiency in the previous studies and showed HDAC1 overexpression is a poor prognostic factor not only in EMC but also in SEC. In CCC, HDAC6 and HDAC7 expressions were upregulated in comparison with other histological subtypes, and that HDAC7 cytoplasmic expression is expected to become a poor prognostic factor. Although HDAC6 nuclear expression had no significant effect on a prognosis in univariate analysis, it was found to have the significant as a poor prognostic factor in multivariate analysis employing FIGO stage, histological subtype, and surgical debulking status. By subgroup analysis, we found that HDAC6 nuclear overexpression is associated with a poor prognosis especially in surgical suboptimal cases. In SEC, the most prominent molecular changes include the alternation in *TP53*, which was exclusively mutations. HDAC1 provides the major enzymes for p53 deacetylation and form a Snail1/HDAC1/p53 tri-molecular complex, and inactivates p53 ([@b14-ol-0-0-7726],[@b19-ol-0-0-7726],[@b20-ol-0-0-7726]). On the other hand, in CCC, *ARID1A* mutation is the most common event (57%) ([@b21-ol-0-0-7726]) and frequently coexists with *PIK3CA* mutation ([@b22-ol-0-0-7726]). HDAC6 activity is essential in *ARID1A*-mutated ovarian cancers and HDAC6 inhibition selectively promoted apoptosis of *ARID1A*-mutated cells ([@b23-ol-0-0-7726]). CCC is associated with Lynch syndrome, which is characterized by germline mutations in MSH2 ([@b24-ol-0-0-7726],[@b25-ol-0-0-7726]). HDAC6 deacetylates and ubiquitinates MSH2, causing a cellular tolerance to DNA damage and decreased cellular DNA mismatch repair activities ([@b26-ol-0-0-7726]). CCC is at a higher level of HIF-1α than other histological subtypes ([@b27-ol-0-0-7726]), and HDAC7 increases transcriptional activity of HIF-1α ([@b28-ol-0-0-7726]). In is suggested that the different HDAC isoforms may become a prognostic factor in SEC, EMC, and CCC. HDAC6 and 7 have a potential of being a chemotherapeutic target specifically for CCC.

HDAC1 and HDAC7 increased after chemotherapy. Residual tumor cells after neo-adjuvant chemotherapy might have low sensitivity or acquired resistance for chemotherapy. HDAC1 and HDAC7 augment cancer stem cell (CSC) phenotype via MiR-34a and the CSC markers such as CD44 and CD166, and the CSC phenotype is associated with chemotherapy resistance, metastasis, and relapse ([@b29-ol-0-0-7726],[@b30-ol-0-0-7726]). HDAC1 directly deacetylates HIF-1α and blocks degradation of the protein ([@b16-ol-0-0-7726]). HDAC7 increases transcriptional activity of HIF-1α through the formation of a complex with HIF-1α, HDAC7, and p300 in the nucleus ([@b28-ol-0-0-7726]). Overexpression of HIF-1α reduced cisplatin-induced apoptosis in cisplatin-sensitive cells ([@b31-ol-0-0-7726]). HDAC inhibitor has been reported to have synergistic cytotoxicity with cisplatin in ovarian carcinoma cells and can restore cisplatin sensitivity in the acquired cisplatin-resistant cells ([@b15-ol-0-0-7726],[@b32-ol-0-0-7726]). HDAC1 and 7 have a potential of being a chemotherapeutic target for ovarian cancer with chemoresistance. It would be useful to clarify the correlation between HDACs and chemoresistance-related substances, such as HIF-1α, CD44, CD166, e-cadherin, MSH2, and PD-L1 etc. A potential weakness of the present study is the small population of several important subgroups, such as EMC (n=36), MUC (n=9), chemotherapy SD+PD group (n=3). Further studies are needed to clarify the precise associations with those factors

In conclusion, this immunohistochemical study of HDACs expression revealed the correlation between the HDAC isoforms and the prognosis and histological subtypes. Further studies, especially focusing on HDAC1, 6, and 7, are needed in order to explore the strategy for histological subtypes of ovarian cancer with chemoresistance or low chemo-sensitivity.
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![A four-tiered scoring system of immunohistochemical expressions. (A) Nuclear expression of HDAC1: 0 for negative cases; +1 for weak intensity; +2 for moderate intensity; and +3 for strong intensity. (B) Cytoplasmic expression of HDAC7: 0 for negative cases; +1 for weak intensity; +2 for moderate intensity; and +3 for strong intensity. HDAC, histone deacetylase.](ol-15-03-3524-g00){#f1-ol-0-0-7726}

![HDACs expression (%) of each histological subtype in each FIGO stage: (A) HDACs expression (%) of each histological subtypes in all FIGO stages. HDACs expression of each FIGO stage in (B) SEC, (C) CCC, and (D) EMC. P-values, Kruskal-Wallis tests. HDAC, histone deacetylase; FIGO, International Federation of Obstetrics and Gynecology; SEC, serous carcinoma; CCC, clear cell carcinoma; EMC, endometrioid carcinoma.](ol-15-03-3524-g01){#f2-ol-0-0-7726}

![Kaplan-Meier survival analysis: Serous carcinoma patients according to the HDAC1 nuclear expression (A, PFS; B, OS) and HDAC7 cytoplasmic expression (C, PFS; D, OS). Endometrioid carcinoma patients according to the HDAC1 nuclear expression (E, PFS; F, OS) and HDAC7 cytoplasmic expression (G, PFS; H, OS). Clear cell carcinoma patients according to the HDAC1 nuclear expression (I, PFS; J, OS) and HDAC7 cytoplasmic expression (K, PFS; L, OS). Serous carcinoma patients according to the HDAC1 nuclear expression in FIGO stage I/II (M, PFS; N, OS) and stage III/IV (O, PFS; P, OS). Clear cell carcinoma patients according to the HDAC1 nuclear expression in FIGO stage I/II (Q, PFS; R, OS) and stage III/IV (S, PFS; T, OS). P-values, log-rank test. HDAC, histone deacetylase; PFS, progression free survival; OS, overall survival; FIGO, International Federation of Obstetrics and Gynecology.](ol-15-03-3524-g02){#f3-ol-0-0-7726}

![Kaplan-Meier survival analysis: OS according to the HDAC6 nuclear expression in all cases (A), SEC (B), CCC (C), EMC (D), FIGO stage I/II (E), stage III/IV (F), optimal surgery (G), and suboptimal surgery (H). P-values, log-rank test. OS, overall survival; HDAC, histone deacetylase; FIGO, International Federation of Obstetrics and Gynecology; SEC, serous carcinoma; CCC, clear cell carcinoma; EMC, endometrioid carcinoma.](ol-15-03-3524-g03){#f4-ol-0-0-7726}

###### 

Clinicopathological characteristics of patients (n=201).

  Variable               No. (%)
  ---------------------- ----------------------
  Age                    
    Median (range)       57.4 (26--84)
    \<50                 57 (28.4)
    ≥50                  144 (71.6)
  Parity                 
    \<2                  64 (31.8)
    ≥2                   137 (68.2)
  Menopause              
    Yes                  57 (28.3)
    No                   144 (71.6)
  CA125 (U/ml)           
    Median (range)       6,383.8 (7--865,591)
    ≥200                 77 (38.3)
    \<200                124 (61.7)
  Treatment              
    OP only              24 (11.9)
    OP+AC                88 (43.8)
    OP+AC+IDS            10 (5.0)
    NAC+IDS              54 (26.9)
    EL+Chemotherapy      18 (9.0)
    Others               7 (3.4)
  Histological subtype   
    Serous               100 (49.7)
    Clear cell           56 (27.9)
    Endometrioid         36 (17.9)
    Mucinous             9 (4.5)
  FIGO stage             
    I                    73 (36.3)
    II                   24 (11.9)
    III                  83 (41.3)
    IV                   21 (10.5)
  Recurrence             
    Yes                  106 (52.7)
    No                   95 (47.3)
  Death                  
    Yes                  65 (32.3)
    No                   136 (67.7)

CA125, cancer antigen 125; OP, standard operation (at least hysterectomy, bilateral adnexectomy, and omentectomy); AC, adjuvant chemotherapy; IDS, interval debulking surgery; NAC, neo-adjuvant chemotherapy; EL, exploratory laparotomy; FIGO, International Federation of Gynecology and Obstetrics.

###### 

HDACs expression (%) before and after chemotherapy.

                 HDAC1 (N)   HDAC2 (N)   HDAC3 (N)   HDAC4 (N)   HDAC4 (C)   HDAC5 (C)   HDAC6 (N)   HDAC6 (C)   HDAC7 (N)   HDAC7 (C)                                                             
  -------------- ----------- ----------- ----------- ----------- ----------- ----------- ----------- ----------- ----------- ----------- ------ ------ --- ------ ----- -------- ----- ------ ---- --------
  All (n=38)                 0.03                    0.37                    0.25                    0.16                    0.77               0.57       0.66         \<0.01         0.01        \<0.01
    Before         76                    66                      21                      21                      34                        79          8          39               0          16   
    After          92                    58                      32                      11                      32                        74          5          74             16           66   
  CR+PR (n=35)               0.06                    0.54                    0.37                    0.16                    0.74               0.37       0.66         0.03           0.02        \<0.01
    Before         77                    66                      20                      23                      34                        80          9          43               0          14   
    After          91                    60                      29                      11                      31                        71          6          77             14           66   
  SD+PD (n=3)                0.42                    0.42                    0.42                    0.42                    1.00               0.42       0.42         0.42           0.42        0.67
    Before         67                    67                      33                      0                       33                        67          0            0              0          33   
    After        100                     33                      67                      0                       33                      100           0          33             33           67   

HDAC, histone deacetylase; (N), nuclear expression; (C), cytoplasmic expression; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; P-values, Wilcoxon signed-rank test.

###### 

Univariable and multivariable analysis using the Cox proportional hazards model of overall survival for ovarian cancer (n=201/65 events).

  A, Univariate analysis                                   
  ---------------------------------- -------- ------------ -------------
  Age (\>50 vs. ≤50)                 1.45     0.89--2.37   0.13
  Histology                                                
    Serous                           1.00                  
    Clear cell                       0.28     0.13--0.58   \<0.01
    Endometrioid                     0.26     0.10--0.66   0.04
    Mucinous                         1.00     0.36--2.78   1.00
  Stage (III/IV vs. I/II)            13.3     5.71--30.8   \<0.01
  Surgery (optimal vs. suboptimal)   7.97     4.30--14.7   \<0.01
  HDAC1 (N)                          2.06     1.10--3.87   0.02
  HDAC2 (N)                          1.25     0.75--2.08   0.39
  HDAC3 (N)                          0.90     0.53--1.53   0.69
  HDAC4 (N)                          0.85     0.51--1.43   0.55
  HDAC4 (C)                          1.16     0.70--1.91   0.57
  HDAC5 (C)                          2.54     1.46--4.42   \<0.01
  HDAC6 (N)                          0.93     0.46--1.89   0.85
  HDAC6 (C)                          1.18     0.72--1.91   0.52
  HDAC7 (N)                          0.14     0.02--1.00   0.05
  HDAC7 (C)                          1.19     0.70--1.99   0.52
                                                           
  **B, Multivariate analysis**                             
                                                           
  **Variables**                      **HR**   **95% Cl**   **P-value**
                                                           
  Stage (III/IV vs. I/II)            10.8     3.67--32.0   \<0.01
  Surgery (optimal vs. suboptimal)   11.1     3.32--37.4   \<0.01
  Histology                                                
    Serous                           1.00                  
    Clear cell                       8.11     2.33--28.3   \<0.01
    Endometrioid                     2.43     0.94--6.30   0.07
    Mucinous                         36.5     8.26--161    \<0.01
  HDAC6(N)                           3.51     1.49--8.27   \<0.01

HR, hazard ratio; CI, indicates confidence interval; (N), nuclear expression; (C), cytoplasmic expression.
